Cargando…
Judicious Use of Lipid Lowering Agents in the Management of NAFLD
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world. NAFLD encompasses a spectrum of histological features, including steatosis, steatohepatitis with balloon degeneration, and hepatic fibrosis leading to cirrhosis. In patients with advance...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313319/ https://www.ncbi.nlm.nih.gov/pubmed/30249980 http://dx.doi.org/10.3390/diseases6040087 |
_version_ | 1783383904913195008 |
---|---|
author | Iqbal, Umair Perumpail, Brandon J. John, Nimy Sallam, Sandy Shah, Neha D. Kwong, Waiyee Cholankeril, George Kim, Donghee Ahmed, Aijaz |
author_facet | Iqbal, Umair Perumpail, Brandon J. John, Nimy Sallam, Sandy Shah, Neha D. Kwong, Waiyee Cholankeril, George Kim, Donghee Ahmed, Aijaz |
author_sort | Iqbal, Umair |
collection | PubMed |
description | Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world. NAFLD encompasses a spectrum of histological features, including steatosis, steatohepatitis with balloon degeneration, and hepatic fibrosis leading to cirrhosis. In patients with advanced liver damage, NAFLD is associated with an increased risk of hepatocellular carcinoma. Diabetes mellitus, hypertension, and dyslipidemia are components of metabolic syndrome and are commonly associated with NAFLD. Cardiovascular disease is the leading cause of mortality in patients with NAFLD. Therefore, it is important to pre-emptively identify and proactively treat conditions like hyperlipidemia in an effort to favorably modify the risk factors associated with cardiovascular events in patients with NAFLD. The management of hyperlipidemia has been shown to reduce cardiovascular mortality and improve histological damage/biochemical abnormalities associated with non-alcoholic steatohepatitis (NASH), a subset of NAFLD with advance liver damage. There are no formal guidelines available regarding the use of anti-hyperlipidemic drugs, as prospective data are lacking. The focus of this article is to discuss the utility of lipid-lowering drugs in patients with NAFLD. |
format | Online Article Text |
id | pubmed-6313319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63133192019-01-04 Judicious Use of Lipid Lowering Agents in the Management of NAFLD Iqbal, Umair Perumpail, Brandon J. John, Nimy Sallam, Sandy Shah, Neha D. Kwong, Waiyee Cholankeril, George Kim, Donghee Ahmed, Aijaz Diseases Review Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world. NAFLD encompasses a spectrum of histological features, including steatosis, steatohepatitis with balloon degeneration, and hepatic fibrosis leading to cirrhosis. In patients with advanced liver damage, NAFLD is associated with an increased risk of hepatocellular carcinoma. Diabetes mellitus, hypertension, and dyslipidemia are components of metabolic syndrome and are commonly associated with NAFLD. Cardiovascular disease is the leading cause of mortality in patients with NAFLD. Therefore, it is important to pre-emptively identify and proactively treat conditions like hyperlipidemia in an effort to favorably modify the risk factors associated with cardiovascular events in patients with NAFLD. The management of hyperlipidemia has been shown to reduce cardiovascular mortality and improve histological damage/biochemical abnormalities associated with non-alcoholic steatohepatitis (NASH), a subset of NAFLD with advance liver damage. There are no formal guidelines available regarding the use of anti-hyperlipidemic drugs, as prospective data are lacking. The focus of this article is to discuss the utility of lipid-lowering drugs in patients with NAFLD. MDPI 2018-09-24 /pmc/articles/PMC6313319/ /pubmed/30249980 http://dx.doi.org/10.3390/diseases6040087 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Iqbal, Umair Perumpail, Brandon J. John, Nimy Sallam, Sandy Shah, Neha D. Kwong, Waiyee Cholankeril, George Kim, Donghee Ahmed, Aijaz Judicious Use of Lipid Lowering Agents in the Management of NAFLD |
title | Judicious Use of Lipid Lowering Agents in the Management of NAFLD |
title_full | Judicious Use of Lipid Lowering Agents in the Management of NAFLD |
title_fullStr | Judicious Use of Lipid Lowering Agents in the Management of NAFLD |
title_full_unstemmed | Judicious Use of Lipid Lowering Agents in the Management of NAFLD |
title_short | Judicious Use of Lipid Lowering Agents in the Management of NAFLD |
title_sort | judicious use of lipid lowering agents in the management of nafld |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313319/ https://www.ncbi.nlm.nih.gov/pubmed/30249980 http://dx.doi.org/10.3390/diseases6040087 |
work_keys_str_mv | AT iqbalumair judicioususeoflipidloweringagentsinthemanagementofnafld AT perumpailbrandonj judicioususeoflipidloweringagentsinthemanagementofnafld AT johnnimy judicioususeoflipidloweringagentsinthemanagementofnafld AT sallamsandy judicioususeoflipidloweringagentsinthemanagementofnafld AT shahnehad judicioususeoflipidloweringagentsinthemanagementofnafld AT kwongwaiyee judicioususeoflipidloweringagentsinthemanagementofnafld AT cholankerilgeorge judicioususeoflipidloweringagentsinthemanagementofnafld AT kimdonghee judicioususeoflipidloweringagentsinthemanagementofnafld AT ahmedaijaz judicioususeoflipidloweringagentsinthemanagementofnafld |